SBD121, a Synbiotic Medical Food for RA Management

Not Applicable

Recruiting

• Conditions: Rheumatoid Arthritis
• Interventions: Other: SBD121; Other: Placebo

• Registration Number: NCT06005220
• Lead Sponsor: Solarea Bio, Inc

Brief Summary

The aim of this randomised, double-blind, placebo controlled clinical food trial is to determine if the medical food SBD121 Synbiotic (prebiotic and probiotic) will aid in the dietary management of symptoms of early rheumatoid arthritis (RA).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-08-07
• Study First Submitted QC: 2023-08-16
• Study First Posted: 2023-08-22
• Study Start: 2023-09-30
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-02
• Last Update Posted: 2025-01-06
• Primary Completion: 2025-06
• Study Completion: 2025-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

1. Willing and able to provide written informed consent prior to the performance of any study-specific procedure and willing to comply with the protocol and report on compliance and side effects during study period.
2. Male or female aged 18 - 75 years inclusive at the time of consent.
3. The participant must have newly diagnosed RA, not exceeding 1-year from diagnosis
4. The participant must have been taking methotrexate (MTX) for treatment of RA for ≤ 75 days before baseline, or will be commencing MTX at the same time as baseline (within range 15 to 25 mg inclusive, recommended target dose of 20mg).
5. The participant must have active RA meeting classification criteria according to the 2010 ACR/EULAR guidelines with a score equal to or greater than 6/10 at screening (11). (Seropositivity is not required).
6. The participant must be available throughout entire study period, willing and able to attend all scheduled visits and in the opinion of the Investigator be able to understand and comply with planned study procedures.
7. Body Mass Index (BMI) between 18.5 and 40 kg/m2
8. Normal cardiovascular parameters (systolic blood pressure ≤ 150 mm Hg, diastolic blood pressure ≤ 90 mm Hg). One re-test is permitted.
9. Women of childbearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test pre-first administration, on Day 1, and must agree to remain sexually abstinent, or use medically effective contraception (refer to Appendix 11.1), or have a partner who is sterile or same-sex, from Screening until end of study. Males must not be planning to father children or donate sperm for the duration of the study.

Exclusion Criteria

1. Participant is currently taking any probiotic or prebiotic supplements, or has taken them in the past 7 days, or is unwilling to avoid taking probiotic/prebiotic supplements for the duration of the study.

2. Participant has any known or suspected allergies to probiotics or prebiotics.

3. Participant has taken oral or parenteral antibiotics within 21 days of screening, requires antibiotics pre-first dose, or is likely to require antibiotics during the study period.

4. Participant has undergone major surgery within last 3-months before screening or planned during the study period

5. Participant is a current or past smoker and/or user of nicotine replacement therapies (including vaping), that in the documented opinion of the Investigator, may adversely affect participation in the study, safety, and/or study outcomes.

6. Participant has a past or current history of drug and/or alcohol abuse at the time of enrolment (the use of illegal drugs or the use of prescription or over-the-counter drugs or alcohol for purposes other than those for which they are meant to be used, or in excessive amounts).

7. Participant has a known history of any of the following (according to Investigator judgement and/or participant report):

   1. Gastric or intestinal dysmotility, slowed transit time, pancreatitis, or inflammatory bowel disease
   2. Known Hepatitis B or Hepatitis C infection, cirrhosis or chronic liver disease
   3. Underlying structural heart disease or previous history of endocarditis or valve replacement
   4. Rheumatic disease other than rheumatoid arthritis, including but not limited to psoriasis, spondyloarthritis, systemic lupus erythematosus, multiple sclerosis
   5. Immunosuppressed, including: known HIV positive; solid organ or stem cell transplant recipient; taking any oral or parenteral immunosuppressive therapy; neutrophil count <500/mm3; or anticipated drop in the neutrophil count to <500/mm3
   6. Any malignancy, with the exception of non-melanoma skin cancers, or other cancer more than 5-years ago
   7. Active tuberculosis (TB) within 3-months prior to Screening
   8. Any infection requiring hospitalisation, or as otherwise judged clinically significant, within 3-months prior to Screening

8. Presence of any of the following active conditions at Screening, or within 72 hours of the first administration of study test article:

   1. Clinically significant abnormal vital signs or physical examination abnormalities (other than those related to RA, such as joint swelling)
   2. Febrile illness (temp. > 37.5 degrees Celsius), or one or more episodes of diarrhoea within 72 hours of the first dose of study test article
   3. Acute abdomen, colitis, or active GI disease
   4. Septicaemia or bacteraemia
   5. Uncontrolled diabetes mellitus, based on medical history and in response to query 'is your diabetes under control?'.

9. Current treatment with any Disease Modifying Arthritis Drug (DMARD) other than methotrexate including but not limited to, hydroxychloroquine, sulfasalazine, and minocycline leflunomide, gold compounds, azathioprine, or cyclosporine will be exclusionary if used within 30 days prior to randomisation.

10. Current or past treatment with any biologic agent including but not limited to tumor necrosis factor (TNF) inhibitors: etanercept, infliximab, adalimumab; interleukin 1 (IL-1) inhibitors: anakinra; lymphocyte directed: abatacept, rituximab; Janus kinase (JAK) inhibitors: tofacitinib; interleukin 17 (IL-17) inhibitors; Interleukin 23 (IL-23) inhibitors.

11. Corticosteroid use from 30 days prior to randomisation until final assessment visit will be exclusionary, with the following exceptions:

    1. Oral corticosteroids in low doses (≤ 10 mg/d prednisone or equivalent) will be allowed if stable for 1-month prior to randomisation. Reduction of dose or use of oral corticosteroids is permissible throughout the study.
    2. Topical, inhaled, or intranasal steroids are permitted
    3. Past use of oral or parenteral (> 10 mg/d prednisone or equivalent) corticosteroids is allowed if not used within 1-month prior to randomisation.

12. Women only - pregnant, planning on becoming pregnant during the trial, breastfeeding, positive urine pregnancy test during Screening or within 24 hours of first administration of study test article.

13. Any of the following abnormal findings on Screening or Baseline laboratory tests (one re-test per timepoint permitted):

    1. White blood cells (WBCs) < lower limit of normal (LLN) or > upper limit of normal (ULN). If WBC is documented within normal range prior to commencing steroids and is deemed by the Investigator as elevated at screening due to recent addition of these drugs and not related to any other comorbidities, then may be suitable to proceed.
    2. Neutrophils < 1500/µl (1.5 x109/L)
    3. Platelets < 100 x 10³/µl (100 x 109/L)
    4. Haemoglobin < 9.0 g/dl (90 g/L)
    5. Serum Creatinine > 1.5 x ULN
    6. Glomerular filtration rate (GFR) of < or = 40 mL/minute
    7. Aspartate aminotransferase (AST) > 3 x ULN
    8. Alanine aminotransferase (ALT) > 3 x ULN
    9. Total Bilirubin > 1.5 x ULN

14. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer participating in the study or would make it unlikely the volunteer could complete the study

15. If the participant has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
SBD121 Medical Food	SBD121	Two capsules administered twice daily with food
Placebo	Placebo	Two capsules administered twice daily with food

Primary Outcome Measures

Name	Time	Method
American College of Rheumatology 20 (ACR-20)	16 Weeks	Evaluate the dietary management of arthritis by the number and percentage of participants achieving American College of Rheumatology 20 (ACR20) response (ie, greater to or equal to 20% improvement in the ACR composite score, a measure of RA symptoms including: joint swelling and tenderness; patient's assessment of pain, arthritis activity, and physical function; physician's assessment of arthritis activity; and CRP) at Week 16

Secondary Outcome Measures

Name	Time	Method
Disease Activity Score 28 - Eosinophil Sedimentation Rate (DAS28 - ESR)	8-weeks, 16-weeks	Evaluate the dietary management of arthritis by the percentage change from baseline value in the Activity Score-28 (DAS-28) with ESR (DAS-28-ESR), and the individual components that make up the DAS-28-ESR \[Tender Joint Count (TJC), Swollen Joint Count (SJC), and Patients Global Assessment of Activity, plus Erythrocyte Sedimentation Rate (ESR)\], at 8 and 16 weeks
Safety by Adverse Events	16-weeks	Number and percentage of participants experiencing adverse events (AEs) and serious adverse events (SAEs)
American College of Rheumatology 70 (ACR-70)	8-weeks, 16-weeks	Evaluate the dietary management of arthritis by the number and percentage of participants achieving ACR70 response in the ACR composite score at Week 8, and Week 16
Disease Activity Score 28 - C-Reactive Protein (DAS28 - CRP)	8-weeks, 16-weeks	Evaluate the dietary management of arthritis by the percentage change from baseline value in the DAS-28 with CRP score and the individual components that make up the DAS-28 CRP Score \[Tender Joint Count (TJC), Swollen Joint Count (SJC), and Patients Global Assessment of Activity, plus C-Reactive Protein (CRP)\], at 8 and 16 weeks
Tolerability by GITQ	16-weeks	Frequency and severity of GI symptoms (e.g., gas, abdominal pain, bloating) as assessed by the Gastrointestinal Tolerability Questionnaire (GITQ) score at each timepoint compared to placebo.
American College of Rheumatology 50 (ACR-50)	8-weeks, 16-weeks	Evaluate the dietary management of arthritis by the number and percentage of participants achieving ACR50 response in the ACR composite score at Week 8, and Week 16
American College of Rheumatology 20 (ACR-20)	8 weeks	Evaluate the dietary management of arthritis by the number and percentage of participants achieving American College of Rheumatology 20 (ACR20) response (ie, greater to or equal to 20% improvement in the ACR composite score, a measure of RA symptoms including: joint swelling and tenderness; patient's assessment of pain, arthritis activity, and physical function; physician's assessment of arthritis activity; and CRP) at Week 8
Disease Activity Score 28 - C-Reactive Protein - Low Disease Activity (DAS28 - CRP LDA)	8-weeks, 16-weeks	Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-CRP Low Activity, defined as DAS-28-CRP Score \< 3.2, at 8 and 16 weeks
Disease Activity Score 28 - C-Reactive Protein - Remission (DAS28 - CRP Remission)	8-weeks, 16-weeks	Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-CRP Remission, defined as DAS-28-CRP Score \< 2.6, at 8 and 16 weeks
C-Reactive Protein (CRP)	8-weeks, 16-weeks	Evaluate the dietary management of arthritis by the improvement in CRP from baseline
Zonulin	8-weeks, 16-weeks	Evaluate improvement in gastrointestinal permeability by improvement in Zonulin from baseline
Disease Activity Score 28 - Eosinophil Sedimentation Rate - Low Disease Activity (DAS28 - ESR - LDA)	8-weeks, 16-weeks	Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-ESR Low Activity defined as DAS-28-ESR Score \< 3.2, at 8 and 16 weeks
Disease Activity Score 28 - Eosinophil Sedimentation Rate - Remission (DAS28 - ESR Remission)	8-weeks, 16-weeks	Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-ESR Remission defined as DAS-28-ESR Score \< 2.6, at 8 and 16 weeks
Reduce or discontinue use of oral NSAIDs	8-weeks, 16-weeks	Evaluate the dietary management of arthritis by the number and percentage of participants able to reduce dose or discontinue use of oral NSAIDs, at 8 and 16 weeks
Eosinophil Sedimentation Rate (ESR)	8-weeks, 16-weeks	Evaluate the dietary management of arthritis by the improvement in ESR from baseline
Reduce or discontinue use of oral corticosteroids	8-weeks, 16-weeks	Evaluate the dietary management of arthritis by the number and percentage of participants able to reduce dose or discontinue use of oral corticosteroids, at 8 and 16 weeks

Trial Locations

Locations (22)

St. Vincents Hospital Melbourne; 🇦🇺 Melbourne, Victoria, Australia

Fiona Stanley Hospital; 🇦🇺 Perth, Western Australia, Australia

Diagnostic Consultative Center 1 - Lom EOOD; 🇧🇬 Lom, Bulgaria

Medical Center - Teodora EOOD; 🇧🇬 Ruse, Bulgaria

MHAT Lyulin EAD, Department of Rheumatology; 🇧🇬 Sofia, Bulgaria

Diagnostic Consultative Center XIV - Sofia EOOD; 🇧🇬 Sofia, Bulgaria

Medical Center Tera Medico EOOD; 🇧🇬 Vrasta, Bulgaria

RTL SM SRL/ IMSP Institutul de Cardiologie; 🇲🇩 Chisinau, Moldova, Republic of

Spitalul Clinic Republican Timofei Mosneaga; 🇲🇩 Chisinau, Moldova, Republic of

Paratus Clinical Canberra; 🇦🇺 Canberra, Australian Capital Territory, Australia

Campbelltown Hospital; 🇦🇺 Campbelltown, New South Wales, Australia

Royal Prince Alfred Hospital; 🇦🇺 Camperdown, New South Wales, Australia

Liverpool Hospital; 🇦🇺 Liverpool, New South Wales, Australia

Princess Alexandra Hospital; 🇦🇺 Woolloongabba, Queensland, Australia

Genesis Research Services; 🇦🇺 Newcastle, New South Wales, Australia

BJC Health; 🇦🇺 Parramatta, New South Wales, Australia

Westmead Hospital; 🇦🇺 Westmead, New South Wales, Australia

Western Health; 🇦🇺 St. Albans, Victoria, Australia

Linear Clinical Trials; 🇦🇺 Nedlands, Western Australia, Australia

Aotearoa Clinical Trials; 🇳🇿 Auckland, New Zealand

Optimal Clinical Trials; 🇳🇿 Auckland, New Zealand

Southern Clinical Trials; 🇳🇿 Nelson, New Zealand